Lanreotid Zentiva (Lanreotide)

Lanreotide is a synthetic analogue of somatostatin. It binds to somatostatin receptors SSTR2 and SSTR5 on pituitary and tumor cells, inhibiting adenylate cyclase, reducing cyclic AMP, and consequently decreasing the release of growth hormone, IGF‑1, and various gastrointestinal hormones that contribute to disease activity.

The specific dose and dosing interval of Lanreotid Zentiva are determined by the prescribing physician based on the individual patient's condition, response to therapy, and clinical guidelines. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for lanreotide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Lanreotid Zentiva (lanreotide) and other agents such as octreotide share a similar mechanism of binding somatostatin receptors, but they differ in formulation, dosing frequency, and pharmacokinetic profiles. Lanreotide is often administered as a long‑acting injectable, allowing less frequent dosing compared with some short‑acting alternatives.

Lanreotid Zentiva should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

The medication is given by subcutaneous injection, typically performed by a healthcare professional. The injection site is rotated to minimise local irritation, and the preparation is used immediately after removal from refrigeration, following aseptic technique.

Serious adverse events, though uncommon, include gallstone formation, significant hyperglycaemia or new‑onset diabetes, pancreatitis, severe allergic reactions such as anaphylaxis, and cardiac arrhythmias. Patients should be monitored regularly for these conditions, and any concerning symptoms reported promptly.

Lanreotid Zentiva is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients. Caution is advised for individuals with severe hepatic or renal impairment, uncontrolled diabetes, active gallbladder disease, or significant cardiac conduction abnormalities, and it should be avoided unless benefits outweigh risks.